A A-A DO2, 152–156 Abgs. See Arterial Blood Gases Accelerating
Index A A-a DO2, 152–156 ABGs. See Arterial blood gases Accelerating waveform, 123 ACMV. See Volume assist-control mode Acute hypoxemic respiratory failure (AHRF), 424–426 Acute respiratory distress syndrome (ARDS) case study, 523–524 characterization criteria, 248–249 historical aspects, 5–6 pathophysiology diffuse alveolar damage (DAD), 251 Starling equation, 250 primary and secondary, 249 ventilatory strategies airway pressures, 253–254 flow waveforms, 254–255 inspiratory time, 259 inverse ratio ventilation, 259 overdistension, 256–258 PEEP, 255–256 permissive hypercapnia, 261–263 prone ventilation, 263–266 recruitment maneuvers, 260–261 respiratory rate, 254 tidal volumes, 253 ventilation modes, 252–253 Acute respiratory failure (ARF). See Noninvasive ventilation (NIV) Adaptive support ventilation (ASV), 109–110 Adjunctive therapies, 479–504 Adenosine triphosphate (ATP), 171 Adsorptive altelectasis, 326–327 Aerosolized antibiotics, 370–371 527 528 Index Aerosol therapy, 486 Airway humidification. See Humidification, airway Airway occlusion pressure, 399 Airway pressure release ventilation (APRV), 97–98 Airway pressures. See Pressure-time scalar Airway resistance (Raw) calculation, 37, 38 Poiseuille’s law, 35 pulmonary elastance (Pel), 35–36 Alarms apnea, 147 high expired minute volume, 143–144 low airway pressure limit, 146 low expired minute volume activating conditions, 142, 143 airway alarm activation, 141, 142 low oxygen concentration (FIO2), 146 oxygen concentration, 146 power failure, 147 two-minute button, 148 upper airway pressure limit, 144–146 upper oxygen concentration (FIO2), 147 Alveolar dead-space, 40 Alveolar ventilation, 42–43 Anatomical dead-space, 40 Antibiotics aerosolized, 370–371 cycling, 374–375 resistance ESBL, 366 MRSA, 368 multi-drug resistance (MDR), 367 principles, 365 selection, 368–370 topical, 362–363 Apnea alarm, 147 APRV.
[Show full text]